Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 4
2021 7
2022 13
2023 11
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.
Holmstroem RB, Nielsen OH, Jacobsen S, Riis LB, Theile S, Bjerrum JT, Vilmann P, Johansen JS, Boisen MK, Eefsen RHL, Marie Svane I, Nielsen DL, Chen IM. Holmstroem RB, et al. J Immunother Cancer. 2022 Sep;10(9):e005111. doi: 10.1136/jitc-2022-005111. J Immunother Cancer. 2022. PMID: 36096534 Free PMC article. Clinical Trial.
Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC).
Chen IM, Johansen JS, Theile S, Hjaltelin JX, Novitski SI, Brunak S, Hasselby JP, Willemoe GL, Lorentzen T, Madsen K, Jensen BV, Wilken EE, Geertsen P, Behrens C, Nolsoe C, Hermann KL, Svane IM, Nielsen D. Chen IM, et al. J Clin Oncol. 2022 Sep 20;40(27):3180-3189. doi: 10.1200/JCO.21.02511. Epub 2022 Apr 27. J Clin Oncol. 2022. PMID: 35476508 Clinical Trial.
Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
Chen IM, Donia M, Chamberlain CA, Jensen AWP, Draghi A, Theile S, Madsen K, Hasselby JP, Toxværd A, Høgdall E, Lorentzen T, Wilken EE, Geertsen P, Svane IM, Johansen JS, Nielsen D. Chen IM, et al. Eur J Cancer. 2023 Feb;180:125-133. doi: 10.1016/j.ejca.2022.11.035. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36592507 Free article. Clinical Trial.
Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.
Mortensen REJ, Holmström MO, Lisle TL, Hasselby JP, Willemoe GL, Met Ö, Marie Svane I, Johansen J, Nielsen DL, Chen IM, Andersen MH. Mortensen REJ, et al. Among authors: chen im. J Immunother Cancer. 2023 Mar;11(3):e006432. doi: 10.1136/jitc-2022-006432. J Immunother Cancer. 2023. PMID: 36948507 Free PMC article. Clinical Trial.
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.
Willumsen N, Jensen C, Green G, Nissen NI, Neely J, Nelson DM, Pedersen RS, Frederiksen P, Chen IM, Boisen MK, Johansen AZ, Madsen DH, Svane IM, Lipton A, Leitzel K, Ali SM, Erler JT, Hurkmans DP, Mathijssen RHJ, Aerts J, Eslam M, George J, Christiansen C, Bissel MJ, Karsdal MA. Willumsen N, et al. Among authors: chen im. Cell Mol Life Sci. 2022 Mar 25;79(4):204. doi: 10.1007/s00018-022-04226-0. Cell Mol Life Sci. 2022. PMID: 35332383 Free PMC article. Review.
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01).
Rasmussen LS, Winther SB, Chen IM, Weber B, Ventzel L, Liposits G, Johansen JS, Detlefsen S, Egendal I, Shim S, Christensen S, Pfeiffer P, Ladekarl M. Rasmussen LS, et al. Among authors: chen im. BMC Cancer. 2023 Jun 16;23(1):552. doi: 10.1186/s12885-023-11035-6. BMC Cancer. 2023. PMID: 37328835 Free PMC article. Clinical Trial.
Type XX Collagen Is Elevated in Circulation of Patients with Solid Tumors.
Thorlacius-Ussing J, Jensen C, Madsen EA, Nissen NI, Manon-Jensen T, Chen IM, Johansen JS, Diab HMH, Jørgensen LN, Karsdal MA, Willumsen N. Thorlacius-Ussing J, et al. Among authors: chen im. Int J Mol Sci. 2022 Apr 8;23(8):4144. doi: 10.3390/ijms23084144. Int J Mol Sci. 2022. PMID: 35456962 Free PMC article.
Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
Lindgaard SC, Sztupinszki Z, Maag E, Chen IM, Johansen AZ, Jensen BV, Bojesen SE, Nielsen DL, Hansen CP, Hasselby JP, Nielsen KR, Szallasi Z, Johansen JS. Lindgaard SC, et al. Among authors: chen im. Clin Cancer Res. 2021 May 1;27(9):2592-2603. doi: 10.1158/1078-0432.CCR-20-4215. Epub 2021 Mar 18. Clin Cancer Res. 2021. PMID: 33737308
Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival.
Gentiluomo M, Corradi C, Vanella G, Johansen AZ, Strobel O, Szentesi A, Milanetto AC, Hegyi P, Kupcinskas J, Tavano F, Neoptolemos JP, Bozzato D, Hackert T, Pezzilli R, Johansen JS, Costello E, Mohelnikova-Duchonova B, van Eijck CHJ, Talar-Wojnarowska R, Hansen CP, Darvasi E, Chen IM, Cavestro GM, Soucek P, Piredda L, Vodicka P, Gazouli M, Arcidiacono PG, Canzian F, Campa D, Capurso G. Gentiluomo M, et al. Among authors: chen im. Sci Rep. 2021 Apr 7;11(1):7570. doi: 10.1038/s41598-021-87130-0. Sci Rep. 2021. PMID: 33828170 Free PMC article.
30 results